Robert Schooley, MD

Robert Schooley, MD

Infectious Disease San Diego, CA

Professor, Medicine, UCSD School of Medicine


Office Address

  • 200 West Arbor Drive Mc 8201
    Ucsd Medical Center
    San Diego, CA 92103
    Phone: (858) 822-0333
    Fax: (858) 822-5362

Robert Schooley, MD

Infectious Disease San Diego, CA

Professor, Medicine, UCSD School of Medicine

Clinical Specialties & Interests

  • Infectious Disease: General Infectious Disease, HIV/AIDS Medicine
  • Clinical Interests: Hepatitis C; HIV-1; International Medicine

Education & Medical Training

  • Johns Hopkins Bayview Medical CenterJohns Hopkins Bayview Medical Center
  • Johns Hopkins University School of MedicineJohns Hopkins University School of Medicine
  • Johns Hopkins UniversityJohns Hopkins University
  • Massachusetts General HospitalMassachusetts General Hospital
  • The Johns Hopkins Hospital
  • Washington and Lee University

Certifications & Licensure

  • CA State Medical LicenseCA State Medical License2005 - 2016
  • CO State Medical LicenseCO State Medical License1990 - 2015
  • American Board of Internal MedicineInternal Medicine, 1977

Awards, Honors, & Recognition

  • Gold DocArnold P. Gold Foundation, 2009
  • Chief Residents’ Clinical TeachingUniversity of California, San Diego, 2007
  • Science of MedicineBonfils-Stanton Foundation, 1999

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Phase I Study of Combination Therapy with L-697, 661 and Zidovudine.  Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari FA, Collier A, Kahn J and the ACTG 184 Protocol Team, J AIDS & Human Retrovirology. 1996; 12:363-70
  • Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel.  Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG and Volberding PA, International AIDS Society-USA. JAMA. 1996; 276:146-54
  • Virologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and Zalcitabine or Didanosine Compared to Zidovudine Monotherapy.  Schooley RT, Raniirez-Ronda C, Lange JMA, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St. Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kingho..., J Infect Dis. 1996; 173:1354-66

Books/Book Chapters

  • AIDS and Other Manifestations of HIV Infection. Chapter: Antiretroviral Chemotherapy Page 827 - 840
    Schooley RT
    Editors: G.P. Wormser.Raven Press, New York
    Edition 4,
  • Mechanisms of Microbial Diseases. Chapter: Human Retroviruses: AIDS and Other Diseases Page 376 - 388
    Schooley RT
    Editors: Engleberg NC, DiRita V and Dermody TS.Lippincott Williams and Wilkins
    Edition 4,
  • Cecil’s Textbook of Internal Medicine. Chapter: Epstein Barr Virus Infection 
    Schooley RT
    Editors: .

Abstracts/Posters

  • Long-term propagation of New World primate T-lymphocytes in vitro. Falk Jr. LA, Silva D, Byington R and Schooley RT, Fifteenth International Leukocyte Culture Conference. Intercell Communicat in Leucocyte Function

Other

  • Therapeutic decision making in 1997. Cotton D, Bartlett J, Schooley R, Gulick R
  • Check, but not checkmate. Schooley RT, Antiviral Therapy. 1997; 2:68-9
  • Antiretroviral chemotherapy. Saag MS and Schooley RT, Curr Clin Top Infect Dis. 1998; 18:154- 79

Grant Support

  • Orally Active Nucleoside Phosphonates For Hepatitis C VirusNational Institute Of Allergy And Infectious Diseases
    2009 - 2012
  • Multiplex Nucleic Acid Detection Devices For The Diagnosis Of Respiratory VirusesNational Institute Of Allergy And Infectious Diseases
    2007 - 2011
  • International ProgramNational Institute Of Allergy And Infectious Diseases
    2006 - 2011
  • Research In Infectious DiseasesNational Institute Of Allergy And Infectious Diseases
    2005 - 2011
  • Biochip Diagnostic Tool For Bt Induced DiseasesNational Institute Of Allergy And Infectious Diseases
    2005 - 2007
  • The Role Of Sex And HCV Co-Infection In HIV TherapyNational Institute Of Allergy And Infectious Diseases
    2004 - 2004
  • ACTG A5116:2 Regimen Trial For HIV SubjectsNational Center For Research Resources
    2004 - 2004
  • U Of Colorado Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases
    2003 - 2004
  • Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases
    2003 - 2003
  • Colorado Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases
    2000 - 2003
  • Chemotherapy/Immunotherapy For HIV InfectionNational Center For Research Resources
    2000 - 2002
  • Subcutaneous IL-2 In Combination With HaartNational Center For Research Resources
    2000 - 2002
  • Dynamics Of HCV Infection During Antiretroviral TherapyNational Center For Research Resources
    2000 - 2002
  • A5025 Phase II Random Study Of Hydroxyurea In Subj On Potent AntiretroviralsNational Center For Research Resources
    1999 - 2002
  • Phase II Stdy Indinavir+Nevirapine+Stavudine In Subj Prev Trtd W/ 141w94/Vx-478National Center For Research Resources
    1999 - 2002
  • Phase II Prolong Virologic Success &Optn For Failure In HIV Sub On IndinavirNational Center For Research Resources
    1999 - 2002
  • Soft Gelatin Capsule Of Saquinavir In Comb WI Ritonavir Or NelfinavirNational Center For Research Resources
    1999 - 2002
  • Phase III Trial:Efavirenz/ Nelfinavir In Combination WI Lamivudine/ZidovudineNational Center For Research Resources
    1999 - 2002
  • Actg384 Protease Inhibitor &/Or NON Nucleoside Reverse Trans InhibitorNational Center For Research Resources
    1999 - 2002
  • Adult ACTG Central GroupNational Institute Of Allergy And Infectious Diseases
    1999 - 2001
  • ACTG 323 Fluconazole As Therapy For Oropharyngeal CandidiasisNational Center For Research Resources
    1999 - 2002
  • ACTG 362 Trials Of Azithromycin Prophylaxis To Prevent MAC DiseaseNational Center For Research Resources
    1999 - 2002
  • ACTG 398, Phase II Trial Of Amprenavir As PART Of Dual Protease InhibNational Center For Research Resources
    1999 - 2002
  • Safety, Tolerability And Pharmacokinetics Of Thalidomide In HIV1 PatientsNational Center For Research Resources
    1998 - 1999
  • Actg368 Indinavir Sulfate, Dmp266 &1592u89 In HIV Infected SubjectsNational Center For Research Resources
    1998 - 2002
  • Actg347 Phase II Study Of 141w94/Vx478 Monotherapy VS 141w94/Vx + ZidovudineNational Center For Research Resources
    1998 - 2000
  • 3 Maintenence Regimens For HIV Subjects REC Zidovudine, Lamivudine, IndinavirNational Center For Research Resources
    1998 - 2002
  • D4T VS DDI VS ZDV PLUS D4T VS ZDV PLUS DDI In HIV Infected PatientsNational Center For Research Resources
    1997 - 1999
  • Evaluation Of STD Therapy VS STD Therapy W/Msl 109 In AIDS Patients W/CmvNational Center For Research Resources
    1997 - 1997
  • Random Dbl-Bld, Combination Of Nucleoside And Triple Convergent Therapy For HIVNational Center For Research Resources
    1997 - 1997
  • Trial To Evaluate Activity Of 141W94 In Patients With HIV InfectionNational Center For Research Resources
    1997 - 1997
  • Delavirdine And ZDV Or Didanosine VS ZDV And DDI Combination TherapyNational Center For Research Resources
    1997 - 1997
  • ACTG 333--Hard Capsule And Soft Capsule Saquinavir VS IndinavirNational Center For Research Resources
    1997 - 1999
  • Phase I/II Open-Label Trial Of Delavirdine Mesylate (Dlv, U-90152s)National Center For Research Resources
    1997 - 1997
  • Virologic Responses To New Nucleoside Regimens After ZDV Or DDI MonotherapyNational Center For Research Resources
    1997 - 2000
  • Interleukin 2 PLUS Antiretroviral Therapy VS Antiretroviral TherapyNational Center For Research Resources
    1997 - 1999
  • Phase II/III Double-Blind Study Of Amytryptilene/Mexiletine For HIV NeuropathyNational Center For Research Resources
    1997 - 1999
  • 1592U89 Alone And With Retrovir For HIV Infection (Glaxo/Wellcome (131-002)National Center For Research Resources
    1997 - 1997
  • Zdv/Ddi Regimens On Measures Of Viral Burden In Early HIV-1 InfectionNational Center For Research Resources
    1997 - 1999
  • Influence Of Risk Status For Disease Progression On The Response To InterventionNational Center For Research Resources
    1997 - 2000
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases
    1997 - 2002
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • ACTG 320 Phase III Indinavir SulfateNational Center For Research Resources
    1997 - 2000
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • ACTG 315 Ritonavir, Zidovudine And Lamivudine In Advanced HIV 1 DiseaseNational Center For Research Resources
    1997 - 2000
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • ACTG 285 Stem Cell Mobilization And Harvesting With FilgrastimNational Center For Research Resources
    1997 - 2000
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases
    1997 - 1999
  • ACTG 175--Monotherapy VS Combination Therapy In HIV PTS, CD4 200-500National Center For Research Resources
    1996 - 1997
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • Dapsone And Atovaquone Study For PCP In HIV Infected PatientsNational Center For Research Resources
    1996 - 1999
  • Adult ACTG Central GroupNational Institute Of Allergy And Infectious Diseases
    1996 - 1998
  • Phase II/III Clarithromycin Regimens For MAC In HIV Positive PatientsNational Center For Research Resources
    1996 - 1997
  • HIV-1 Derived Immunogens In Infected Individuals W/500 CD4 Cells/Mm3National Center For Research Resources
    1996 - 1997
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases
    1996 - 1999
  • 1592U89 Alone And With Retrovir For HIV InfectionNational Center For Research Resources
    1996 - 1996
  • Conference On Immunopathogenesis Of HIV InfectionNational Institute Of Allergy And Infectious Diseases
    1996 - 1996
  • Short Term Clinical And Virologic Significance Of ZDV ResistanceNational Center For Research Resources
    1996 - 1996
  • ACTG 303--Influence Of Risk Status For Disease ProgressionNational Center For Research Resources
    1996 - 1996
  • ACTG 193a--Nucleoside And Triple Convergent Therapy For HIVNational Center For Research Resources
    1996 - 1996
  • ACTG 276--Various Zdv/Ddi Regimens On Measures Of Viral BurdenNational Center For Research Resources
    1996 - 1996
  • ACTG 261--Delavirdine And ZDV VS ZDV And DDI Combination TherapyNational Center For Research Resources
    1996 - 1996
  • ACTG 260--Phase I/II Trial Of Delavirdine MesylateNational Center For Research Resources
    1996 - 1996
  • ACTG 259--Phase II SC 49483 With ZDV Versus ZDVNational Center For Research Resources
    1996 - 1996
  • ACTG 248--Interleukin 2 PLUS Antiretroviral Therapy VS Antiretroviral TherapyNational Center For Research Resources
    1996 - 1996
  • ACTG 241--Ddi PLUS Nevirapine Versus ZDV PLUS DDINational Center For Research Resources
    1996 - 1996
  • ACTG 209--Phase I/II Trial Vaccine Therapy In HIV1 Infected IndividualsNational Center For Research Resources
    1996 - 1996
  • ACTG 206--Alpha Interferon With DDI For Patients With Kaposis SarcomaNational Center For Research Resources
    1996 - 1996
  • ACTG 204a--Valacyclovir Hydrocholoride Study In HIV Positive PatientsNational Center For Research Resources
    1996 - 1996
  • ACTG 290-D4t VS DDI VS ZDV PLUS D4T VS ZDV PLUS DDI In HIV Positive PatientsNational Center For Research Resources
    1996 - 1996
  • Ribozymes As Molecular Therapies For AIDSNational Institute Of Allergy And Infectious Diseases
    1994 - 1996
  • AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases
    1994 - 1995
  • University Of Colorado HIV Research Training ProgramNational Institute Of Allergy And Infectious Diseases
    1992 - 2003
  • Colorado AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases
    1992 - 1993
  • Cell Mediated Immune Response To Human RetrovirusesNational Cancer Institute
    1990 - 1994
  • AIDS &Related Research 1 Study SectionCenter For Scientific Review
    1990 - 1990
  • Cellular Immune Response To HIVNational Cancer Institute
    1987 - 1989
  • Human T-Cell Leukemia Virus--Virus-Host InteractionsNational Cancer Institute
    1985 - 1986

Committees

  • NIH Drug Discovery and Resistance (DDR) Study Section Chair 2011 - 2013
  • Scientific Advisory Board, PEPFAR, US Department of State Member 2011 - Present

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • BCBS Blue Card PPO
  • BCBS California CaliforniaCare HMO
  • BCBS California PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • First Health PPO
  • Great West PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PHCS PPO - Kaiser
  • Multiplan PPO
  • Pacificare HMO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
  • The full profile is locked and available to verified physicians only.
    Join over 50% of U.S. physicians already on Doximity and get access to this and over 700,000 physician CVs. Find your physician profile

Physicians, view Dr. Schooley's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV

© 2015 Doximity, Inc.HelpBlogCompanyContactPrivacyDirectory